About us

Furher non-dilutive funding of EUR 2.5M is granted the Polish National Centre for Research and Development (NCBR). New investors join the company, securing all private financing necessary to carry out both PARP and NCBR grants over the upcoming period of intense regulatory, preclinical and clinical development of the InFlow valve.

I4HV is granted a Seal of Excellence by the European Innovation Council. Non-dilutive, non-returnable funding of ca. EUR 7M is granted by the Polish Agency for Enterprise Development (PARP).

First international investor joins I4HV, allowing for the purchase of all IP rights by the company from the other members of the initial InFlow consortium. Grant applications are submitted in order to obtain sufficient funding for further development.

Two more patents are granted for additional InFlow valve-related inventions: “Delivery system for implants used in structural heart diseases by a minimally invasive method” and “Method of forming prefabricated units used in production of systems of prosthetic aortic valve transcatheter implantation”.

First patents are granted for two crucial InFlow valve-related inventions: “Biological low profile, balloon expandable prosthetic heart valve, particularly aortic, for transcatheter implantation and the method of its manufacturing” and “A low profile balloon expandable artificial aortic prosthetic heart valve for transcatheter implantation”.

Biological and artificial valve test outcomes: short- and long-term (30 – 180 days) observation confirmed feasibility and safety as well as excellent hemodynamic function and high biocompatibility of the InFlow valves.

An ovine banding model of aortic stenosis for stable TAVI fixation is developed. Two separate pre-clinical feasibility studies are launched with biological and artificial aortic valves, involving 24 and 26 sheep respectively.

An operational prototype of the InFlow valve is obtained. Fatigue tests show significant resistance to unwanted damage. A preclinical study protocol is prepared and ethics committee approval secured.

An innovative method of combining aortic valve components to form a vent is developed. Biological material and polymeric composites used to create valve leaflets are selected, with the prevention of thrombosis and degeneration of the new valve in mind.

Specialists in the fields of biomechanics, engineering and medicine develop the core technology concepts behind the first iteration of the INFLOW valve and its delivery system.

INFLOW project launch – a public-private consortium led by prof. Paweł Buszman begins the development of a novel transcatheter aortic valve implant (TAVI), with two variants – biological and polymeric.

Several inventions are developed, with two European patents later granted for: “Intravascular microcatheter for delivering active substances” and “Intravascular microcatheter for delivering active substances”

The company is joined by Piotr Hirnle MSc, thus establishing the core group of specialists in the fields of medicine, finance and management, who had long been engaged in the development of new and innovative medical technologies.

Establishment of the company Innovations for Heart and Vessels Ltd. (I4HV) by professor Paweł Buszman MD, PhD and his son Piotr Buszman MD, PhD – both of whom are key opinion leaders in interventional cardiology, with extensive scientific and business backgrounds.